Fisher & Paykel Healthcare Corporation Limited revised earnings guidance for the financial year ending 31 March 2024. The full year guidance previously provided on 29 November 2023, based on a NZ:US exchange rate of 58 cents, was for operating revenue to be approximately $1.7 billion and net profit after tax to be in the range of approximately $250 million to $260 million. Now, assuming a NZ:US exchange rate of approximately 61 cents for the balance of the financial year, the company expects full year operating revenue to be approximately $1.73 billion and underlying profit after tax (excluding any fair value changes) to be in the range of approximately $260 million to $265 million.
Fisher & Paykel Healthcare Corporation Limited
Equities
FPH
NZFAPE0001S2
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.99 NZD | +2.15% | +5.86% | +18.60% |
Apr. 09 | New Zealand Shares Fall for Second Day; Fisher & Paykel Healthcare Launches Apnea Mask | MT |
Apr. 09 | Fisher & Paykel Begins Selling Lightest Mask for Sleep Apnea | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.60% | 9.49B | |
-2.54% | 187B | |
-1.85% | 106B | |
-4.26% | 66.9B | |
+1.39% | 49.45B | |
+16.82% | 48B | |
+4.06% | 40.84B | |
+3.49% | 26.48B | |
+0.65% | 26.25B | |
+12.96% | 24.62B |
- Stock Market
- Equities
- FPH Stock
- News Fisher & Paykel Healthcare Corporation Limited
- Fisher & Paykel Healthcare Corporation Limited Revises Earnings Guidance for the Financial Year Ending 31 March 2024